JP2023551980A5 - - Google Patents
Info
- Publication number
- JP2023551980A5 JP2023551980A5 JP2023534290A JP2023534290A JP2023551980A5 JP 2023551980 A5 JP2023551980 A5 JP 2023551980A5 JP 2023534290 A JP2023534290 A JP 2023534290A JP 2023534290 A JP2023534290 A JP 2023534290A JP 2023551980 A5 JP2023551980 A5 JP 2023551980A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- product according
- pharmaceutical product
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122042P | 2020-12-07 | 2020-12-07 | |
| US63/122,042 | 2020-12-07 | ||
| PCT/EP2021/084659 WO2022122765A2 (en) | 2020-12-07 | 2021-12-07 | Antibody and taxane combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551980A JP2023551980A (ja) | 2023-12-13 |
| JP2023551980A5 true JP2023551980A5 (https=) | 2024-12-13 |
Family
ID=79165020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534290A Pending JP2023551980A (ja) | 2020-12-07 | 2021-12-07 | 抗体およびタキソンの併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240109972A1 (https=) |
| EP (1) | EP4255575A2 (https=) |
| JP (1) | JP2023551980A (https=) |
| KR (1) | KR20230128482A (https=) |
| CN (1) | CN117083080A (https=) |
| AU (1) | AU2021393908A1 (https=) |
| CA (1) | CA3200895A1 (https=) |
| IL (1) | IL303424A (https=) |
| MX (1) | MX2023006404A (https=) |
| TW (1) | TW202237081A (https=) |
| WO (1) | WO2022122765A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| US20260034201A1 (en) * | 2022-07-20 | 2026-02-05 | Biontech Us Inc. | Combination therapy with neoantigen vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| KR100745488B1 (ko) * | 2006-07-04 | 2007-08-02 | 학교법인 울산공업학원 | 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| JP2017507900A (ja) * | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| SI3242890T1 (sl) | 2015-01-08 | 2020-01-31 | BioNTech SE | Agonistična sredstva, ki vežejo receptorje TNF |
| SG11202000198QA (en) * | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| TWI719765B (zh) * | 2018-12-19 | 2021-02-21 | 美商建南德克公司 | 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療 |
-
2021
- 2021-12-07 TW TW110145714A patent/TW202237081A/zh unknown
- 2021-12-07 KR KR1020237023103A patent/KR20230128482A/ko active Pending
- 2021-12-07 IL IL303424A patent/IL303424A/en unknown
- 2021-12-07 JP JP2023534290A patent/JP2023551980A/ja active Pending
- 2021-12-07 EP EP21834759.9A patent/EP4255575A2/en active Pending
- 2021-12-07 AU AU2021393908A patent/AU2021393908A1/en active Pending
- 2021-12-07 WO PCT/EP2021/084659 patent/WO2022122765A2/en not_active Ceased
- 2021-12-07 CN CN202180092643.1A patent/CN117083080A/zh active Pending
- 2021-12-07 MX MX2023006404A patent/MX2023006404A/es unknown
- 2021-12-07 US US18/038,818 patent/US20240109972A1/en active Pending
- 2021-12-07 CA CA3200895A patent/CA3200895A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI795347B (zh) | 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌 | |
| CA2715166C (en) | Monoclonal antibodies for tumor treatment | |
| TWI908743B (zh) | 抗dll3藥劑之給藥方案 | |
| JP2024525758A5 (https=) | ||
| US20250011418A1 (en) | Cancer specific plectin-1 specific antibodies and methods of use thereof | |
| JP2022541591A5 (https=) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023551980A5 (https=) | ||
| CN121079315A (zh) | 用于组合疗法的方法和组合物 | |
| JP2024536383A5 (https=) | ||
| US20220211846A1 (en) | Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers | |
| TW202545570A (zh) | 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用 | |
| WO2025082449A1 (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| CN119587691A (zh) | 抗her2抗体药物偶联物联合抗her2抗体治疗肿瘤 | |
| JP2024523438A5 (https=) | ||
| JP2024538755A5 (https=) | ||
| CN120344271A (zh) | 抗her2抗体药物偶联物治疗乳腺癌 | |
| JP2024502465A5 (https=) | ||
| AU2020410527A1 (en) | Treatment with site specific HER2 antibody-drug conjugates | |
| WO2026021442A1 (zh) | 抗体药物偶联物在制备治疗肺癌的药物中的用途 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| WO2026077321A1 (zh) | 抗her2抗体药物偶联物和免疫检查点抑制剂的药物组合 | |
| WO2025252203A1 (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤的用途 | |
| WO2024177899A1 (en) | Methods for treating non-small cell lung cancer with anti-pd-1 antibodies | |
| WO2024216028A1 (en) | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |